Quantisnow Logo
Dashboard

Amendment: SEC Form SC 13G/A filed by Immunome Inc.

$IMNM
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $IMNM alert in real time by email
SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 IMMUNOME INC COMMON STOCK Cusip #45257U108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #45257U108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,222,540 Item 6: 0 Item 7: 4,224,700 Item 8: 0 Item 9: 4,224,700 Item 11: 7.034% Item 12: HC Cusip #45257U108 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 4,224,700 Item 8: 0 Item 9: 4,224,700 Item 11: 7.034% Item 12: IN Item 1(a). Name of Issuer: IMMUNOME INC Item 1(b). Address of Issuer's Principal Executive Offices: 18702 N. CREEK PARKWAY, SUITE 100 BOTHELL, WA 98011 US Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 45257U108 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 4,224,700 (b) Percent of Class: 7.034% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 4,224,700 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of IMMUNOME INC. No one other person's interest in the COMMON STOCK of IMMUNOME INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of IMMUNOME INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
Get the next $IMNM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMNM

DatePrice TargetRatingAnalyst
11/8/2024$30.00Overweight
Stephens
5/31/2024$27.00Overweight
Piper Sandler
4/30/2024$24.00Overweight
JP Morgan
4/15/2024$35.00Buy
Guggenheim
1/29/2024$30.00Outperform
Leerink Partners
12/19/2023$12.00Outperform
Wedbush
10/29/2021$35.00Overweight
Cantor Fitzgerald
More analyst ratings

$IMNM
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer

    Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately. "We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant

    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 3, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 51,000 shares of common stock to four new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to

    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    Immunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 22,258,064 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,903,225 shares, at a price to the public of $7.75 per share. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, were $172.5 million. All of the shares in the offering were sold by Immunome. J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities acted as join

    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$IMNM
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$IMNM
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$IMNM
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$IMNM
 SEC Filings

See more

$IMNM
 Leadership Updates

Live Leadership Updates

See more

  • Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer

    Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately. "We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant

    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Immunome Appoints Roee Shahar as Executive Vice President, Commercial

    Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.

    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors

    Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today the appointment of Dr. Purnanand Sarma, PhD, as Chair of its Board of Directors. Dr. Sarma, who will hold the title of Executive Chairman, will actively support the strategic development of STALICLA, working closely with the CEO, Lynn Durham, and the management team. With an

    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$IMNM
 Financials

Live finance-specific insights

See more

  • Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

    Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments. "2023 was a transformative year for Immunome as we closed the merger with Morphimmune, advanced our pipeline and expanded the company's leadership team," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Th

    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Immunome Reports Third Quarter 2023 Financial Results

    - Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - - Bob Lechleider, M.D., appointed as Chief Medical Officer – - Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors - - Cash runway expected to extend into Q1 2026* - Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Immunome Reports Fourth Quarter and Full Year 2022 Financial Results

    Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update. "Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response," stated Purnanand Sarma, Ph.D., President and CEO of Immunome. "We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our p

    $IMNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

$IMNM
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more